Prothena公司宣布从诺和诺德获得与Coramitug(前称Prx004)治疗ATTR淀粉样变性心肌病持续三期临床试验相关的5000万美元临床里程碑付款

美股速递
Mar 10

Prothena公司宣布,其合作伙伴诺和诺德已向公司支付5000万美元的临床里程碑款项。该笔款项的触发与Coramitug(曾用代号Prx004)用于治疗转甲状腺素蛋白淀粉样变性心肌病的三期临床试验进展相关。目前,该项关键性临床试验正在持续推进中。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10